Provenienza dei contatti di primo grado di Samir Ounzain
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.
4
| Holding Company | Biotechnology | 4 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Samir Ounzain tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
CONCERT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
RAPID MICRO BIOSYSTEMS, INC. | Industrial Machinery | Director/Board Member | |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | President | |
The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree | |
IMUGENE LIMITED | Biotechnology | Director/Board Member | |
GPC Biotech, Inc.
GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Drugstore Chains | Corporate Officer/Principal | |
University of Kansas | College/University | Doctorate Degree | |
ENANTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Universität Konstanz | College/University | Doctorate Degree | |
TVM Capital Corp.
TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Broadview Ventures, Inc.
Broadview Ventures, Inc. Investment ManagersFinance Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Biohealth Innovation, Inc.
Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Financial Conglomerates | Director/Board Member | |
Action Potential Venture Capital
Action Potential Venture Capital Investment ManagersFinance Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom. | Investment Managers | Director/Board Member | |
ZappRx, Inc.
ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Gladius Pharmaceuticals Corp.
Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Biotechnology | Director/Board Member | |
DECIBEL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | Investment Managers | Private Equity Investor | |
Palleon Pharma, Inc.
Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Pharmaceuticals: Major | Director/Board Member | |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Monitor Deloitte
Monitor Deloitte Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Monitor Deloitte is a company that provides strategic consulting services. The company is based in Rosslyn, VA. The company was founded by Lene S Schulze. | Miscellaneous Commercial Services | Consultant / Advisor | |
Samsara Therapeutics, Inc.
Samsara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Samsara Therapeutics, Inc. operates as a biopharmaceutical platform company. It engages in the development and commercialization of first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. The company was founded by Sebastian Aguiar in 2018 and is headquartered in Lewes, DE. | Pharmaceuticals: Major | Chief Executive Officer | |
Cleara Biotech BV
Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
METAGENOMI, INC. | Pharmaceuticals: Major | Founder | |
Berkeley University of California | College/University | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
Stati Uniti | 30 |
Germania | 3 |
Australia | 2 |
Canada | 2 |
Paesi Bassi | 2 |
Settori
Health Technology | 18 |
Finance | 7 |
Consumer Services | 6 |
Commercial Services | 5 |
Producer Manufacturing | 2 |
Posizioni
Director/Board Member | 23 |
Private Equity Investor | 5 |
Chairman | 4 |
Chief Executive Officer | 4 |
Corporate Officer/Principal | 3 |
Contatti più connessi
Insiders | |
---|---|
Jens Eckstein | 27 |
Benjamin Kreitman | 5 |
Brian Thomas | 5 |
Daniel Blessing | 1 |
- Borsa valori
- Insiders
- Samir Ounzain
- Connessioni Società